Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among Intensive Care Unit Patients

Overview

Journal Indian J Crit Care Med

Specialty Critical Care

Date 2017 Aug 16

PMID 28808360

Citations 3

Authors

Mohamed Sayed Abbas

Affiliations

Soon will be listed here.

Abstract

Background: Critically ill patients are considered a high-risk group for developing venous thromboembolism (VTE). Due to their impaired cardiopulmonary reserve, these VTEs may result in significant morbidity and mortality. In this study, we compared two types of low molecular weight heparin, enoxaparin, and bemiparin, as regards to their efficacy and safety in VTE prevention among Intensive Care Unit (ICU) patients.

Methods: This study was a prospective, randomized trial of 100 critically ill patients who are at high risk for developing VTE were included in this study and assigned to receive subcutaneous injections of either 3500 international units (IU) anti-factor Xa of bemiparin sodium or 40 mg of enoxaparin given once a day and patient were followed for 60 days after initiation of anticoagulant therapy for the development of documented deep venous thrombosis (DVT) using bilateral lower limb venous duplex, documented pulmonary embolism using computed tomography pulmonary angiography, and complications related to injectant anticoagulant.

Results: Confirmed DVT was observed in two patients (4%) in the bemiparin group compared with 10 patients (20%) in the enoxaparin group with < 0.05. Confirmed pulmonary embolism (PE) was observed in seven patients (14%) in the enoxaparin group with no recorded cases of confirmed PE in the bemiparin group ( < 0.05). No deaths were recorded in either group. Adverse events such as ecchymosis or hematoma at the injection site were observed in one patient (2%) in the bemiparin group and eight patients (16%) in the enoxaparin group ( < 0.05). There was no significant statistical difference between both groups as regards other adverse effects and complications related to the injectant anticoagulant.

Conclusion: Bemiparin was superior to enoxaparin as a prophylactic anticoagulant for VTE in critically ill patients with less adverse local complications at the injection site. The study was registered on www.clinicaltrials.gov. Registration ID: NCT02795065. Registered June 8, 2016.

Citing Articles

Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis.

Eck R, Elling T, Sutton A, Wetterslev J, Gluud C, van der Horst I BMJ. 2022; 378:e070022.

PMID: 35788047 PMC: 9251634. DOI: 10.1136/bmj-2022-070022.

Randomized Trial of Deep Vein Thrombosis Chemoprophylaxis with Bemiparin and Enoxaparin in Patients with Moderate to High Thrombogenic Risk Undergoing Plastic and Reconstructive Surgery Procedures.

Revilla-Penaloza F, Olsoff-Pagovich P, Ochoa-Gomez J, Castaneda-Gaxiola R, Rubio-Gayosso A, Ceballos G Aesthetic Plast Surg. 2019; 44(3):820-829.

PMID: 31853609 DOI: 10.1007/s00266-019-01573-5.

Thromboprophylaxis in Intensive Care Unit Patients: A Literature Review.

Ejaz A, Ahmed M, Tasleem A, Niazi M, Ahsraf M, Ahmad I Cureus. 2018; 10(9):e3341.

PMID: 30473974 PMC: 6248708. DOI: 10.7759/cureus.3341.

References

Dalen J . Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis. Chest. 2002; 122(4):1440-56. DOI: 10.1378/chest.122.4.1440. View

Kelly J, Rudd A, Lewis R, Hunt B . Venous thromboembolism after acute stroke. Stroke. 2001; 32(1):262-7. DOI: 10.1161/01.str.32.1.262. View

Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D . Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005; 33(7):1565-71. DOI: 10.1097/01.ccm.0000171207.95319.b2. View

Zierler B . Ultrasonography and diagnosis of venous thromboembolism. Circulation. 2004; 109(12 Suppl 1):I9-14. DOI: 10.1161/01.CIR.0000122870.22669.4a. View

Crowther M, Cook D, Griffith L, Devereaux P, Rabbat C, Clarke F . Deep venous thrombosis: clinically silent in the intensive care unit. J Crit Care. 2005; 20(4):334-40. DOI: 10.1016/j.jcrc.2005.09.011. View

Attia J, Ray J, Cook D, Douketis J, Ginsberg J, Geerts W . Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med. 2001; 161(10):1268-79. DOI: 10.1001/archinte.161.10.1268. View

Navarro-Quilis A, Castellet E, Rocha E, Paz-Jimenez J, Planes A . Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J Thromb Haemost. 2003; 1(3):425-32. DOI: 10.1046/j.1538-7836.2003.00142.x. View

McCarthy S, Turner J . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing. 1986; 15(2):84-8. DOI: 10.1093/ageing/15.2.84. View

Balibrea J, Altimiras J, Larruzea I, Gomez-Outes A, Martinez-Gonzalez J, Rocha E . Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int J Surg. 2007; 5(2):114-9. DOI: 10.1016/j.ijsu.2006.07.005. View

10.

Cosmi B, Palareti G . Old and new heparins. Thromb Res. 2011; 129(3):388-91. DOI: 10.1016/j.thromres.2011.11.008. View

11.

Robinson S, Zincuk A, Larsen U, Ekstrom C, Nybo M, Rasmussen B . A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial. Crit Care. 2013; 17(2):R75. PMC: 4057520. DOI: 10.1186/cc12684. View

12.

McCarthy S, Turner J, Robertson D, Hawkey C, Macey D . Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet. 1977; 2(8042):800-1. DOI: 10.1016/s0140-6736(77)90728-0. View

13.

Ibrahim E, Iregui M, Prentice D, Sherman G, Kollef M, Shannon W . Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med. 2002; 30(4):771-4. DOI: 10.1097/00003246-200204000-00008. View

14.

Ciccone M, Cortese F, Corbo F, Corrales N, Al-Momen A, Silva A . Bemiparin, an effective and safe low molecular weight heparin: a review. Vascul Pharmacol. 2014; 62(1):32-7. DOI: 10.1016/j.vph.2014.03.001. View

15.

Desciak M, Martin D . Perioperative pulmonary embolism: diagnosis and anesthetic management. J Clin Anesth. 2011; 23(2):153-65. DOI: 10.1016/j.jclinane.2010.06.011. View

16.

Wittram C, Maher M, Yoo A, Kalra M, Shepard J, McLoud T . CT angiography of pulmonary embolism: diagnostic criteria and causes of misdiagnosis. Radiographics. 2004; 24(5):1219-38. DOI: 10.1148/rg.245045008. View

17.

Alalaf S, Jawad R, Muhammad P, Ali M, Al Tawil N . Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial. BMC Pregnancy Childbirth. 2015; 15:72. PMC: 4377203. DOI: 10.1186/s12884-015-0515-2. View

18.

Robinson S, Zincuk A, Strom T, Larsen T, Rasmussen B, Toft P . Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care. 2010; 14(2):R41. PMC: 2887151. DOI: 10.1186/cc8924. View

19.

Cade J . High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982; 10(7):448-50. DOI: 10.1097/00003246-198207000-00006. View

20.

Fraisse F, Holzapfel L, Couland J, Simonneau G, Bedock B, Feissel M . Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1109-14. DOI: 10.1164/ajrccm.161.4.9807025. View